The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration
Open accessAbstract
Parkinson's Disease (PD) is an age-related, chronic neurodegenerative disorder. At present, there are no disease-modifying therapies to prevent PD progression. Activated microglia and neuroinflammation are associated with the pathogenesis and progression of PD. Accumulation of α-synuclein (α-SYN) in the brain is a core feature of PD and leads to microglial activation, inflammatory cytokine/chemokine production, and ultimately to neurodegeneration. Given the importance of the JAK/STAT pathway in activating microglia and inducing cytokine/chemokine expression, we investigated the therapeutic potential of inhibiting the JAK/STAT pathway using the JAK1/2 inhibitor, AZD1480.In vitro, α-SYN exposure activated the JAK/STAT pathway in microglia and macrophages, and treatment with AZD1480 inhibited α-SYN-induced major histocompatibility complex Class II and inflammatory gene expression in microglia and macrophages by reducing STAT1 and STAT3 activation. For in vivo studies, we used a rat model of PD induced by viral overexpression of α-SYN. AZD1480 treatment inhibited α-SYN-induced neuroinflammation by suppressing microglial activation, macrophage and CD4+T-cell infiltration and production of proinflammatory cytokines/chemokines. Numerous genes involved in cell–cell signaling, nervous system development and function, inflammatory diseases/processes, and neurological diseases are enhanced in the substantia nigra of rats with α-SYN overexpression, and inhibited upon treatment with AZD1480. Importantly, inhibition of the JAK/STAT pathway prevented the degeneration of dopaminergic neurons in vivo. These results indicate that inhibiting the JAK/STAT pathway can prevent neuroinflammation and neurodegeneration by suppressing activation of innate and adaptive immune responses to α-SYN. Furthermore, this suggests the feasibility of targeting the JAK/STAT pathway as a neuroprotective therapy for neurodegenerative diseases. SIGNIFICANCE STATEMENT α-SYN plays a central role in the pathophysiology of PD through initiation of neuroinflammatory responses. Using an α-SYN overexpression PD model, we demonstrate a beneficial therapeutic effect of AZD1480, a specific inhibitor of JAK1/2, in suppressing neuroinflammation and neurodegeneration. Our findings document that inhibition of the JAK/STAT pathway influences both innate and adaptive immune responses by suppressing α-SYN-induced microglia and macrophage activation and CD4+T-cell recruitment into the CNS, ultimately suppressing neurodegeneration. These findings are the first documentation that suppression of the JAK/STAT pathway disrupts the circuitry of neuroinflammation and neurodegeneration, thus attenuating PD pathogenesis. JAK inhibitors may be a viable therapeutic option for the treatment of PD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Genetic missense mutations or duplications of the -SYN gene lead to familial forms of PD by increased expression and aggregation (Polymeropoulos et al., 1997; Singleton et al., 2003).”
BackgroundThe M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 1×
“It is important to stress that proinflammatory and anti-inflammatory phenotypes do not necessarily exclude each other and often coexist (Martinez and Gordon, 2014).”
Backgroundα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Immunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190
Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130
IL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses
Krausgruber, T., Blazek, K., Smallie, T., Alzabin, S., Lockstone, H., Sahgal, N., Hussell, T., Feldmann, M., & Udalova, I. A. (2011) · Nature Immunology · doi:10.1038/ni.1990 · Cited by 1,306
Dong, Y., & Benveniste, E. N. (2001) · Glia · doi:10.1002/glia.1107 · Cited by 1,293
Self-citationZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 1×
“Oligomeric -SYN is a potent activator of microglia and macrophages via engagement of toll-like receptors, leading to production of proinflammatory mediators (Zhang et al., 2005; Béraud and Maguire-Zeiss, 2012; Fellner et al., 2013; Kim et al., 2013; Daniele et al., 2015).”
BackgroundBrochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
O'Shea, J. J., & Plenge, R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,138
Hu, X., & Ivashkiv, L. B. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.002 · Cited by 928
Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3549 · Cited by 869
Kim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 1×
“Oligomeric -SYN is a potent activator of microglia and macrophages via engagement of toll-like receptors, leading to production of proinflammatory mediators (Zhang et al., 2005; Béraud and Maguire-Zeiss, 2012; Fellner et al., 2013; Kim et al., 2013; Daniele et al., 2015).”
BackgroundHamza, T. H., Zabetian, C. P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., Kay, D. M., Doheny, K. F., Paschall, J., Pugh, E., et al. (2010) · Nature Genetics · doi:10.1038/ng.642 · Cited by 784
Missing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Toll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia
Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., Wenning, G. K., & Stefanova, N. (2013) · Glia · doi:10.1002/glia.22437 · Cited by 697
Neuroinflammation in Parkinson's disease
Hirsch, E. C., Vyas, S., & Hunot, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70065-7 · Cited by 657
Microglia Induce Motor Neuron Death via the Classical NF-κB Pathway in Amyotrophic Lateral Sclerosis
Frakes, A. E., Ferraiuolo, L., Haidet-Phillips, A. M., Schmelzer, L., Braun, L., Miranda, C. J., Ladner, K. J., Bevan, A. K., Foust, K. D., Godbout, J. P., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.013 · Cited by 638 · cited 1×
“…detrimental effects in a number of neurologic diseases, including multiple sclerosis (MS), Alzheimer’s disease, ALS, and spinal cord injury (Kigerl et al., 2009; Appel et al., 2010; Hawthorne and Popovich, 2011; Kannarkat et al., 2013; Benveniste et al., 2014; Frakes et al., 2014; Moehle, 2015).”
BackgroundMechanisms of Jak/STAT Signaling in Immunity and Disease
Villarino, A. V., Kanno, Y., Ferdinand, J. R., & O’Shea, J. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401867 · Cited by 552
Unravelling mononuclear phagocyte heterogeneity
Geissmann, F., Gordon, S., Hume, D. A., Mowat, A. M., & Randolph, G. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2784 · Cited by 529
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A., Buettner, R., Proia, D., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 526
Self-citationPolarization of the Effects of Autoimmune and Neurodegenerative Risk Alleles in Leukocytes
Raj, T., Rothamel, K., Mostafavi, S., Ye, C., Lee, M. N., Replogle, J. M., Feng, T., Lee, M., Asinovski, N., Frohlich, I., et al. (2014) · Science · doi:10.1126/science.1249547 · Cited by 506
Classic and New Animal Models of Parkinson's Disease
Blesa, J., Phani, S., Jackson-Lewis, V., & Przedborski, S. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/845618 · Cited by 505
LRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463
Self-citationGhosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., & Pahan, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704908104 · Cited by 438
Reynolds, A. D., Stone, D. K., Hutter, J. A. L., Benner, E. J., Mosley, R. L., & Gendelman, H. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901852 · Cited by 406
Harms, A. S., Cao, S., Rowse, A. L., Thome, A. D., Li, X., Mangieri, L. R., Cron, R. Q., Shacka, J. J., Raman, C., & Standaert, D. G. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5610-12.2013 · Cited by 406
Self-citationTheodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 367
Self-citationMHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration
Cebrián, C., Zucca, F. A., Mauri, P., Steinbeck, J. A., Studer, L., Scherzer, C. R., Kanter, E., Budhu, S., Mandelbaum, J., Vonsattel, J. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4633 · Cited by 338
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324 · cited 3×
“Proinflammatory macrophages and microglia have detrimental effects in a number of neurologic diseases, including multiple sclerosis (MS), Alzheimer’s disease, ALS, and spinal cord injury (Kigerl et al., 2009; Appel et al., 2010; Hawthorne and Popovich, 2011; Kannarkat et al., 2013; Benveniste et al., 2014; Frakes et a…”
BackgroundCD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease
Saunders, J. A. H., Estes, K. A., Kosloski, L. M., Allen, H. E., Dempsey, K. M., Torres-Russotto, D. R., Meza, J. L., Santamaria, P. M., Bertoni, J. M., Murman, D. L., et al. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9402-z · Cited by 323
Self-citationPeripheral Inflammatory Biomarkers and Risk of Parkinson's Disease
Chen, H., O'Reilly, E. J., Schwarzschild, M. A., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm260 · Cited by 317
Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons
Mount, M. P., Lira, A., Grimes, D., Smith, P. D., Faucher, S., Slack, R., Anisman, H., Hayley, S., & Park, D. S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5321-06.2007 · Cited by 315
Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases
Lee, H.-J., Bae, E.-J., & Lee, S.-J. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.275 · Cited by 306
Daniele, S. G., Béraud, D., Davenport, C., Cheng, K., Yin, H., & Maguire-Zeiss, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.2005965 · Cited by 303 · cited 1×
“Oligomeric -SYN is a potent activator of microglia and macrophages via engagement of toll-like receptors, leading to production of proinflammatory mediators (Zhang et al., 2005; Béraud and Maguire-Zeiss, 2012; Fellner et al., 2013; Kim et al., 2013; Daniele et al., 2015).”
BackgroundInflammatory dysregulation of blood monocytes in Parkinson’s disease patients
Grozdanov, V., Bliederhaeuser, C., Ruf, W. P., Roth, V., Fundel-Clemens, K., Zondler, L., Brenner, D., Martin-Villalba, A., Hengerer, B., Kassubek, J., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1345-4 · Cited by 295
Gorbatyuk, O. S., Li, S., Sullivan, L. F., Chen, W., Kondrikova, G., Manfredsson, F. P., Mandel, R. J., & Muzyczka, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711053105 · Cited by 293
Decressac, M., Mattsson, B., Lundblad, M., Weikop, P., & Björklund, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.013 · Cited by 286
Epigenome-wide differences in pathology-free regions of multiple sclerosis–affected brains
Huynh, J. L., Garg, P., Thin, T. H., Yoo, S., Dutta, R., Trapp, B. D., Haroutunian, V., Zhu, J., Donovan, M. J., Sharp, A. J., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3588 · Cited by 279
Qin, H., Yeh, W.-I., De Sarno, P., Holdbrooks, A. T., Liu, Y., Muldowney, M. T., Reynolds, S. L., Yanagisawa, L. L., Fox, T. H., Park, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117218109 · Cited by 263
Self-citationAppel, S. H., Beers, D. R., & Henkel, J. S. (2010) · Trends in Immunology · doi:10.1016/j.it.2009.09.003 · Cited by 256 · cited 3×
“Proinflammatory macrophages and microglia have detrimental effects in a number of neurologic diseases, including multiple sclerosis (MS), Alzheimer’s disease, ALS, and spinal cord injury (Kigerl et al., 2009; Appel et al., 2010; Hawthorne and Popovich, 2011; Kannarkat et al., 2013; Benveniste et al., 2014; Frakes et a…”
BackgroundInflammation and Adaptive Immunity in Parkinson's Disease
Mosley, R. L., Hutter-Saunders, J. A., Stone, D. K., & Gendelman, H. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009381 · Cited by 247
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Self-citationJakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P., & O'Shea, J. J. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.008 · Cited by 233
Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats
Daher, J. P. L., Volpicelli-Daley, L. A., Blackburn, J. P., Moehle, M. S., & West, A. B. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403215111 · Cited by 223
M1 and M2 immune activation in Parkinson’s Disease: Foe and ally?
Moehle, M. S., & West, A. B. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.018 · Cited by 200
The relation between α-synuclein and microglia in Parkinson’s disease: Recent developments
Sanchez-Guajardo, V., Tentillier, N., & Romero-Ramos, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.02.008 · Cited by 172
Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease
Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P. P., et al. (2013) · Scientific Reports · doi:10.1038/srep01393 · Cited by 164 · cited 1×
“Ionized calcium binding adaptor molecule 1 (Iba1) was used as marker for activated microglia (Barkholt et al., 2012; Noelker et al., 2013).”
MethodLiu, Y., Holdbrooks, A. T., Sarno, P. D., Rowse, A. L., Yanagisawa, L. L., McFarland, B. C., Harrington, L. E., Raman, C., Sabbaj, S., Benveniste, E. N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301513 · Cited by 159
Self-citationMisfolded α-synuclein and toll-like receptors: therapeutic targets for Parkinson's disease
Béraud, D., & Maguire‐Zeiss, K. A. (2011) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70008-6 · Cited by 135
Benveniste, E. N., Liu, Y., McFarland, B. C., & Qin, H. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0012 · Cited by 123
Self-citationSánchez-Guajardo, V., Annibali, A., Jensen, P. H., & Romero‐Ramos, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31829768d2 · Cited by 117
Lee, Y. J., & Benveniste, E. N. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.4.1559 · Cited by 113
Self-citationNF-κB and STAT3 in glioblastoma: therapeutic targets coming of age
Gray, G. K., McFarland, B. C., Nozell, S. E., & Benveniste, E. N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.964211 · Cited by 109
Self-citationImmunological features of α‐synuclein in Parkinson's disease
Roodveldt, C., Christodoulou, J., & Dobson, C. M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00450.x · Cited by 106
Emerging Concepts in Myeloid Cell Biology after Spinal Cord Injury
Hawthorne, A. L., & Popovich, P. G. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0032-6 · Cited by 100
IFN‐β‐induced SOCS‐1 negatively regulates CD40 gene expression in macrophages and microglia
Qin, H., Wilson, C. A., Lee, S. J., & Benveniste, E. N. (2006) · The FASEB Journal · doi:10.1096/fj.05-5493fje · Cited by 96
Self-citationCao, S., Theodore, S., & Standaert, D. G. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-42 · Cited by 95
Self-citationOlson, K. E., Kosloski, L. M., Anderson, K. M., Diggs, B. J., Clark, B. E., Gledhill, J. M., Shandler, S. J., Mosley, R. L., & Gendelman, H. E. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2131-15.2015 · Cited by 92
der Perren, A. V., Macchi, F., Toelen, J., Carlon, M. S., Maris, M., de Loor, H., Kuypers, D. R. J., Gijsbers, R., den Haute, C. V., Debyser, Z., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.01.014 · Cited by 89
Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma
McFarland, B. C., Ma, J., Langford, C. P., Gillespie, G. Y., Yu, H., Zheng, Y., Nozell, S. E., Huszar, D., & Benveniste, E. N. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0480 · Cited by 89
Self-citationCharacterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease
Funk, N., Wieghofer, P., Grimm, S., Schäfer, R., Bühring, H., Gasser, T., & Biskup, S. (2013) · Movement Disorders · doi:10.1002/mds.25300 · Cited by 85
Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification
Chakrabarty, P., Ceballos‐Diaz, C., Lin, W.-L., Beccard, A., Jansen‐West, K. R., McFarland, N. R., Janus, C., Dickson, D. W., Das, P., & Golde, T. E. (2011) · Nature Neuroscience · doi:10.1038/nn.2829 · Cited by 80
Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates
Barkholt, P., Sánchez-Guajardo, V., Kirik, D., & Romero‐Ramos, M. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.02.004 · Cited by 77
Liu, Y., Holdbrooks, A. T., Meares, G. P., Buckley, J. A., Benveniste, E. N., & Qin, H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403063 · Cited by 71
Self-citationRegulation of the neurodegenerative process associated to Parkinson's disease by CD4+ T-cells
González, H., Contreras, F., & Pacheco, R. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9618-9 · Cited by 70
Nikcevich, K. M., Piskurich, J. F., Hellendall, R. P., Wang, Y., & Ting, J. P. ‐. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00117-4 · Cited by 54
Biomarkers for Parkinson’s Disease
Sherer, T. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002488 · Cited by 46
Vaccination strategies for Parkinson disease: Induction of a swift attack or raising tolerance?
Romero‐Ramos, M., Chelpin, M. V. E., & Sánchez-Guajardo, V. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28578 · Cited by 42
Generation of a α-synuclein-based rat model of Parkinson's disease
Recchia, A., Rota, D., Debetto, P., Peroni, D., Guidolin, D., Negro, A., Skaper, S. D., & Giusti, P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.11.002 · Cited by 39
ICAM-5: A Neuronal Dendritic Adhesion Molecule Involved in Immune and Neuronal Functions
Gahmberg, C. G., Ning, L., & Paetau, S. (2013) · Advances in neurobiology · doi:10.1007/978-1-4614-8090-7_6 · Cited by 33
Adamski, J., & Benveniste, E. N. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0270 · Cited by 21
Self-citationWagoner, N. J. V., O'Keefe, G. M., & Benveniste, E. N. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00010-1 · Cited by 8
Self-citation
Cited by
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Signaling pathways and targeted therapy for myocardial infarction
Zhang, Q., Wang, L., Wang, S., Cheng, H., Xu, L., Pei, G., Wang, Y., Fu, C., Jiang, Y., He, C., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00925-z · Cited by 831
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Microglia Phenotypes in Aging and Neurodegenerative Diseases
Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336
Metadata
- Authors
- Qin, H., Buckley, J. A., Li, X., Liu, Y., Fox, T. H., Meares, G. P., Yu, H., Yan, Z., Harms, A. S., Li, Y., Standaert, D. G., & Benveniste, E. N.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2016-05-04
- Volume
- 36
- Issue
- 18
- Pages
- 5144-5159
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2346322633
- Cited by
- 274
- References
- 80
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.